Immunotherapy shows promise against Hard-to-Treat colorectal cancer
NCT ID NCT06428487
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in the removed tissue. The study is now complete, and results will show how well this approach works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prolgolimab (an immunotherapy drug given as an infusion)
What this could lead to
If successful, this could point toward a way to shrink or eliminate colorectal tumors before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia